208
Participants
Start Date
May 19, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
January 31, 2026
WES analysis
"Whole-exome sequencing will be performed as the first approach in all the recruited patients. First, we will analyze different subsets of genes, belonging to:~1. Maternal effect genes as SCMC components and other related genes;~2. Genes essential in the maturation of the oocyte and zygote progression through the early phases of the embryogenesis or highly expressed at different stages of oocyte maturation;~3. Genes with known and potential roles in the establishment and control of genomic imprinting and involved in DNA methylation reactions.~Subsequently, variants with a high pathogenicity score will be analyzed, to identify any genes that may be associated with the phenomenon, but do not belong to the previously described categories of genes. Finally, we will conduct a whole genome sequencing (WGS) analysis on a selected subgroup of BWS mothers with peculiar clinical histories and negative WES analysis, to explore all the noncoding and regulatory regions not targeted by WES."
whole-genome methylation analysis
A whole-genome methylation analysis will be performed to identify methylation changes in women with reproductive problems including those with offspring affected by BWS
RECRUITING
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
RECRUITING
Istituto Auxologico Italiano, Milan
Istituto Auxologico Italiano
OTHER
University of Campania Luigi Vanvitelli
OTHER
Federico II University
OTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
OTHER